VistaGen Therapeutics, Inc. (VSTA) to Further Advance LiverSafe 3D™ Technology via Strategic Collaboration with Celsis
Today before the opening bell, VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, announced it has entered a new collaboration agreement with Celsis In Vitro Technologies (“Celsis”), the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction, and toxicity screening. The two companies aim to characterize and functionally benchmark VistaGen’s human liver cell platform, LiverSafe 3D™, for studying and predicting human liver drug metabolism. Utilizing Celsis’ experience and expertise in in vitro drug metabolism, VistaGen aims to demonstrate the accuracy of its human liver cell platform.…